This cancer diagnostic company could make you wealthier, just not seven-figures wealthier.
News & Analysis: Exact Sciences
Q1 results were mixed, but the company’s strategy may be key for top-line growth ahead.
EXAS earnings call for the period ending March 31, 2020.
These stocks have a track record of revenue growth, and more is to come.
These two companies have exciting growth opportunities ahead and could make your money work for you.
The growth stock has become a value stock.
Have these growth stocks bottomed out? That's probably the wrong question to ask.
More coronavirus worries. More misery for these healthcare stocks.
Investors should prepare for the genetic testing industry to see a tangible slowdown in volumes due to the coronavirus pandemic.
We're officially in a bear market.